



Treatment of Ras/Raf WT mCRC Based on Sidedness: Guideline Recommendations and Expert Faculty Perspectives

Treatment Recommendations

| Primary Location | ESMO | NCCN | Faculty Perspectives |
|------------------|---|--|--|
| Left | EGFR mAbs are standard of care in first-line setting | No clear preference for EGFR mAbs or bevacizumab in first-line setting | EGFR mAbs are preferred; bevacizumab can be used in select patients in first-line setting |
| Right | EGFR mAbs can be considered in first-line setting if response is goal | No EGFR mAbs in first-line setting and potentially not in any line | No EGFR mAbs in first-line setting (if RR is goal, consider triplet), but consider EGFR mAbs in later line |

References

1. NCCN. Colon cancer. V1.2019.
2. Yoshino T, et al. *Ann Oncol*. 2018;29:44-70.

